118 related articles for article (PubMed ID: 32673260)
21. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
[TBL] [Abstract][Full Text] [Related]
22. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada.
Nouch S; Gallagher L; Erickson M; Elbaharia R; Zhang W; Wang L; Bacani N; Kason D; Kleban H; Knebel L; Hall D; Barrios R; Hull M
Int J Drug Policy; 2018 Sep; 59():76-84. PubMed ID: 30048877
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
[TBL] [Abstract][Full Text] [Related]
25. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of decentralised, task-shifted hepatitis C testing and treatment services in urban Myanmar: implications for scale-up.
Draper BL; Yee WL; Shilton S; Bowring A; Htay H; Nwe N; Markby J; Kyi KP; Easterbrook P; Naing W; Win TM; Aung KS; Howell J; Pedrana A; Hellard M
BMJ Open; 2022 May; 12(5):e059639. PubMed ID: 35504640
[TBL] [Abstract][Full Text] [Related]
28. Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.
Schütz A; Moser S; Schwanke C; Schubert R; Luhn J; Gutic E; Lang T; Schleicher M; Haltmayer H; Gschwantler M
J Viral Hepat; 2018 Jul; 25(7):870-873. PubMed ID: 29316001
[TBL] [Abstract][Full Text] [Related]
29. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.
Cacoub P; Vautier M; Desbois AC; Lafuma A; Saadoun D
Liver Int; 2017 Dec; 37(12):1805-1813. PubMed ID: 28467688
[TBL] [Abstract][Full Text] [Related]
31. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
Singal AG; Lim JK; Kanwal F
Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
[TBL] [Abstract][Full Text] [Related]
32. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
Madden A; Hopwood M; Neale J; Treloar C
PLoS One; 2018; 13(11):e0207226. PubMed ID: 30500863
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain.
Turnes J; Domínguez-Hernández R; Casado MÁ
Gastroenterol Hepatol; 2017; 40(7):433-446. PubMed ID: 28645446
[TBL] [Abstract][Full Text] [Related]
34. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis.
Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):754-767. PubMed ID: 30245064
[TBL] [Abstract][Full Text] [Related]
35. Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.
Valerio H; McAuley A; Innes H; Palmateer N; Goldberg DJ; Munro A; Taylor A; Hutchinson SJ
Int J Drug Policy; 2018 Feb; 52():115-122. PubMed ID: 29414462
[TBL] [Abstract][Full Text] [Related]
36. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
[TBL] [Abstract][Full Text] [Related]
37. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade.
Lazarus JV; Pericàs JM; Picchio C; Cernosa J; Hoekstra M; Luhmann N; Maticic M; Read P; Robinson EM; Dillon JF
J Intern Med; 2019 Nov; 286(5):503-525. PubMed ID: 31472002
[TBL] [Abstract][Full Text] [Related]
38. A pilot study to expand treatment of chronic hepatitis C in resource-limited settings.
Mathur P; Comstock E; McSweegan E; Mercer N; Kumar NS; Kottilil S
Antiviral Res; 2017 Oct; 146():184-190. PubMed ID: 28927676
[TBL] [Abstract][Full Text] [Related]
39. Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care.
McCombe G; Swan D; O'Connor E; Avramovic G; Vickerman P; Ward Z; Surey J; Macías J; Lambert JS; Cullen W
JMIR Res Protoc; 2018 Jun; 7(6):e149. PubMed ID: 29866641
[TBL] [Abstract][Full Text] [Related]
40. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.
Norton BL; Fleming J; Bachhuber MA; Steinman M; DeLuca J; Cunningham CO; Johnson N; Laraque F; Litwin AH
Int J Drug Policy; 2017 Sep; 47():196-201. PubMed ID: 28811158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]